Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: Merck remains confident in TIGIT; Otezla and Sotyktu battle for share in psoriasis; GSK chief warns about worsening UK pharma sector; China plans to ban gene editing technology exports; and an interview with Boehringer Ingelheim’s head of human pharma regions.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 10 February 2023, including: Merck & Co., Inc. remains confident in TIGIT; Otezla and Sotyktu battle for share in psoriasis; GSK plc chief warns about worsening UK pharma sector; China plans to ban gene editing technology exports; and an interview with Boehringer Ingelheim GmbH’s head of human pharma regions.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Merck & Co. Remains 'Very Confident' In TIGIT" - Scrip, 2 Feb, 2023.)
(Also see "Amgen’s Otezla And BMS’s Sotyktu Battle For Share In Oral Psoriasis Drug Market" - Scrip, 6 Feb, 2023.)
(Also see "Worsening UK Pharma Sector Close To ‘Tipping Point,’ Warns GSK Chief" - Scrip, 6 Feb, 2023.)
(Also see "China Planning To Ban Gene Editing Technology Exports" - Scrip, 6 Feb, 2023.)
(Also see "Profile: Boehringer’s Andersen On Volleyball And Leadership Learnings, Storytelling" - Scrip, 3 Feb, 2023.)